Research & Publications

Research has always been be a central component of Lifedoc’s clinical framework, enabling us to provide quality and compassion driven healthcare. Our research emphasis helps us maintain accurate evidence to support our care strategies, ensuring that our patients receive the absolute best quality care. It also allows Lifedoc to fulfill its goal of establishing itself as a reference model for researchers and practitioners studying the conditions and prevention of cardio metabolic conditions.

Take a look at some of our current trials, studies, etc as well as some of our past publications and findings below.

Interested in this research and working with us?
Please contact us here.

Quality care for all. A kid playing doctor.
Published: Primary Care Diabetes
Date:
Authors: Ramfis Nieto-Martínez, Juan P González-Rivas, Eunice Ugel, Maritza Duran, Eric Dávila, Ramez Constantino, Alberto García, Jeffrey I Mechanick, María Inés Marulanda
Abstract:
No previous study in Venezuela and few in the Region of the Americas have reported national cardiometabolic health data. Objectives: To determine the prevalence and distribution of cardiometabolic risk factors (CMRF) in adults of Venezuela.
Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health
Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Published: Diabetes Care
Date:
Authors: William I Sivitz 1 , Lawrence S Phillips 2 3 , Deborah J Wexler 4 , Stephen P Fortmann 5 , Anne W Camp 6 , Margaret Tiktin 7 , Magalys Perez 6 , Jacqueline Craig 8 , Priscilla A Hollander 9 , Andrea Cherrington 10 , Vanita R Aroda 11 , Meng Hee Tan 12 , Jonathan Krakoff 13 , Neda Rasouli 14 , Nicole M Butera 15 , Naji Younes 15 , GRADE Research Group
Abstract:
We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.
Published: The Lancet Global Health
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)—Americas Working Group
Abstract:
Describing the prevalence and trends of cardiometabolic risk factors that are associated with non-communicable diseases (NCDs) is crucial for monitoring progress, planning prevention, and providing evidence to support policy efforts. We aimed to analyze the transition in body-mass index (BMI), obesity, blood pressure, raised blood pressure, and diabetes in the Americas, between 1980 and 2014.
Published: The Lancet Global Health
Date:
Authors: Safia S Jiwani 1 , Rodrigo M Carrillo-Larco 2 , Akram Hernández-Vásquez 3 , Tonatiuh Barrientos-Gutiérrez 4 , Ana Basto-Abreu 4 , Laura Gutierrez 5 , Vilma Irazola 5 , Ramfis Nieto-Martínez 6 , Bruno P Nunes 7 , Diana C Parra 8 , J Jaime Miranda 9
Abstract:
Background: The burden of obesity differs by socioeconomic status. We aimed to characterize the prevalence of obesity among adult men and women in Latin America and the Caribbean by socioeconomic measures and the shifting obesity burden over time.
Published: Primary Care Diabetes
Date:
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Eunice Ugel 3 , Maria Ines Marulanda 4 , Maritza Durán 5 , Jeffrey I Mechanick 6 , Pablo Aschner 7
Abstract:
To evaluate the performance of the Latin American Finnish Diabetes Risk Score (LA-FINDRISC) compared with the original O-FINDRISC in general population. To establish the best cut-off to detect unknown type 2 diabetes (uT2D) and prediabetes.
Published: Diabetes Technology & Therapeutics
Date:
Authors: Mary E Larkin 1 , David M Nathan 1 , Ionut Bebu 2 , Heidi Krause-Steinrauf 2 , William H Herman 3 , John M Higgins 4 5 , Margaret Tiktin 6 , Robert M Cohen 7 , Claire Lund 2 , Richard M Bergenstal 8 , Mary L Johnson 8 , Valerie Arends 9 , GRADE Research Group
Abstract:
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study has enrolled a racially and ethnically diverse population with type 2 diabetes, performed extensive phenotyping, and randomly assigned the participants to one of four second-line diabetes medications.
Published: Diabetes Care
Date:
Authors: Deborah J Wexler 1 , Heidi Krause-Steinrauf 2 , Jill P Crandall 3 , Hermes J Florez 4 , Sophia H Hox 5 , Alexander Kuhn 6 , Ajay Sood 7 , Chantal Underkofler 8 , Vanita R Aroda 6 , GRADE Research Group
Abstract:
GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) is a 36-center unmasked, parallel treatment group, randomized controlled trial evaluating four diabetes medications added to metformin in people with type 2 diabetes (T2DM).
Published: Primary Care Diabetes
Date:
Authors: Juan Pablo González-Rivas 1 , William Polonsky 2 , María María Infante-García 3 , Maritza Duran 4 , Eunice Ugel 5 , María Ines Marulanda 6 , Jeffrey I Mechanick 7 , Ramfis Nieto-Martínez 8
Abstract:
Evidence suggests that depression is more common in patients with diabetes than in the general population. However, contradictory results expose controversy in this association.
1 2 3 6

Contact Us